急性冠状动脉综合征后的常规β-阻断剂治疗:一个时代的结束?
Nicolas Johner1, Baris Gencer1,2,3, Marco Roffi1
1Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
European journal of clinical investigation
|September 11, 2024
概括
在急性冠状动脉综合征 (ACS) 发生后,对于保存左心室 (LV) 缩功能的患者,不再定期推β-阻断剂治疗. 最近的试验表明,在这个人群中没有益处,这挑战了长期以来的做法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 贝塔抑制剂治疗历史上减少了急性冠状动脉综合征 (ACS) 后的死亡率.
- 潜在的益处包括抗失常效应和改善左心室 (LV) 重塑.
- 当代的治疗方法,如再注射疗法,已经改变了β-阻断剂的风险-益处概况.
研究的目的:
- 审查在ACS后使用β-阻断剂的当代证据.
- 评估β阻塞剂在LVEF (LVEF) 保存的患者中的作用.
主要方法:
- 对PubMed搜索的文献进行叙事审查.
- 随机对照试验和观察性研究的分析.
主要成果:
- 在REDUCE-AMI试验中,没有发现维护LVEF的心肌梗塞后β-阻塞剂的益处.
- 减少LVEF的患者的益处仍然很明显.
- 观察数据表明,在LVEF>40%的患者中,超过1-12个月的潜在益处损失.
结论:
- 在ACS后的患者中,应放弃常规的β-阻断剂处方,这些患者的LV静脉缩功能被保留.
- 对于轻度减少LVEF (41%-49%) 的患者,需要进一步研究.
相关概念视频
Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
543
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
543
Adrenergic Antagonists: ɑ and β-Receptor Blockers
420
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
420
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
548
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
548
Antihypertensive Drugs: Types of β-Blockers
603
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
603
Antianginal Drugs: Nitrates and β-Blockers
543
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
543


